Literature DB >> 26076838

Hyponatremia following esclicarbazepine therapy.

Durgesh K Gupta1, Sanjeev K Bhoi1, Jayantee Kalita1, Usha K Misra2.   

Abstract

PURPOSE: To evaluate the safety of eslicarbazepine acetate (ESL) in new onset elderly poststroke seizure patients, especially with respect to hyponatremia.
METHOD: In a two year, single center open labeled observational study of ESL in patients with imaging proven stroke with new onset post stroke seizure were included. ESL was titrated between 400mg and 1200 mg once daily during 1 month observation period. The titrated dose of ESL was continued during 96-week maintenance period. The patients were followed up for seizure control and side effects, including serum sodium on first examination, at the end of 1 month and then at three monthly intervals for 24 months (total eight visits). RESULT: Hyponatremia developed in four out of 32 (12.5%) patients; it was symptomatic in three and asymptomatic in one patient. No statistically significant difference between mean sodium levels at different time period, compared to baseline was found.
CONCLUSION: High incidence of hyponatremia in ESL treated post stroke patients, was found, hyponatremia symptoms since can be subtle and delayed, so monitoring of serum sodium in the patients on ESL treatment is recommended especially in elderly.
Copyright © 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiepileptic; Esclicarbazepine; Hyponatremia; Poststroke; Seizure

Mesh:

Substances:

Year:  2015        PMID: 26076838     DOI: 10.1016/j.seizure.2015.03.005

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  10 in total

Review 1.  Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 2.  Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing Treatment.

Authors:  Charlotte S Kwok; Emily L Johnson; Gregory L Krauss
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

Review 3.  The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Authors:  Paul LaPenna; Laura M Tormoehlen
Journal:  J Med Toxicol       Date:  2017-08-16

Review 4.  Sodium Channel Blockers in the Treatment of Epilepsy.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

5.  Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

Review 6.  Practical Use of Newer Antiepileptic Drugs as Adjunctive Therapy in Focal Epilepsy.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

Review 7.  Acute Symptomatic Seizures Caused by Electrolyte Disturbances.

Authors:  Raffaele Nardone; Francesco Brigo; Eugen Trinka
Journal:  J Clin Neurol       Date:  2016-01       Impact factor: 3.077

8.  Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients.

Authors:  Annika Hilgers; Marion Schaefer
Journal:  Drugs Real World Outcomes       Date:  2016-05-25

Review 9.  Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.

Authors:  Graciana L Galiana; Angela C Gauthier; Richard H Mattson
Journal:  Drugs R D       Date:  2017-09

10.  Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy.

Authors:  Robert T Wechsler; Rodney A Radtke; Michael Smith; David G Vossler; Laura Strom; Eugen Trinka; Hailong Cheng; Todd Grinnell; David Blum; Mariana Vieira; Joana Moreira; Francisco Rocha
Journal:  Epilepsia       Date:  2019-07-01       Impact factor: 5.864

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.